EDAP Announces Preliminary Unaudited Full Year 2016 Revenue
23 February 2017 - 11:31PM
EDAP Announces Preliminary Unaudited Full Year
2016 Revenue
- Full year 2016 revenue increased to approximately €35.6
million
- 2016 HIFU revenues recorded over 63% growth
- Strong cash position of €22 million
- Company to announce fourth quarter and full year 2016 results
April 3rd with accompanying conference call April 4th
LYON, France, February 23, 2017 - EDAP TMS SA (NASDAQ: EDAP),
the global leader in therapeutic ultrasound, announced today that
its unaudited Fourth Quarter 2016 revenue is estimated to be €10.7
million and its full year 2016 revenues to be around €35.6 million,
an increase of 10% as compared to revenue of €32.3 million for the
full year 2015.
The Company estimates that as of December 31, 2016, it had €22
million of cash on hand.
Marc Oczachowski, Chief Executive Officer, commented: "We are
pleased with our 2016 revenue and EDAP's continued growth, mainly
driven by 63% growth in our HIFU division. With €22 million of cash
on hand at the end of the year, we are well positioned to pursue
our development programs and marketing expansion strategy to make
our innovative HIFU technology available worldwide."
The Company also announced that it will report fourth quarter
and full year 2016 results after the close of the market on Monday,
April 3rd, 2017. An accompanying conference call will be hosted by
Marc Oczachowski, CEO and Francois Dietsch, Chief Financial Officer
at 8:30 AM ET on Tuesday, April 4th, 2017. Please refer to the
information below for conference call dial-in information and
webcast registration.
Conference Details
Conference Date: Tuesday, April 4th, 2017 8:30
AM ET
Conference dial-in: 877-269-7756
International dial-in: 201-689-7817
Conference Call Name: EDAP-TMS Fourth Quarter
and Full Year 2016 Results Call
Webcast Registration: Click Here
Following the live call, a replay will be available on the
Company's website, www.edap-tms.com under "Investors
Information."
About EDAP TMS SA
EDAP TMS SA today markets Ablatherm® for high-intensity focused
ultrasound (HIFU) for prostate tissue ablation in the U.S. and for
treatment of localized prostate cancer in the rest of the world.
HIFU treatment is shown to be a minimally invasive and effective
option for prostatic tissue ablation with a low occurrence of side
effects. Ablatherm-HIFU is generally recommended for patients with
localized prostate cancer (stages T1-T2) who are not candidates for
surgery or who prefer an alternative option, or for patients who
failed radiotherapy treatment. Ablatherm-HIFU is approved for
commercial distribution in Europe and some other countries
including Mexico, Chile, Brazil and Canada, and has received 510(k)
clearance by the U.S. FDA. The Company also markets an innovative
robot-assisted HIFU device, the Focal One®, dedicated to focal
therapy of prostate cancer. Focal One® is CE marked but is not FDA
approved. The Company also develops its HIFU technology for the
potential treatment of certain other types of tumors. EDAP TMS SA
also produces and distributes medical equipment (the Sonolith®
lithotripters' range) for the treatment of urinary tract
stones using extra-corporeal shockwave lithotripsy (ESWL) in most
countries including Canada and the U.S. For more information on the
Company, please visit http://www.edap-tms.com, and
http://www.hifu-planet.com.
Important Cautions Regarding Forward-looking
Statements
In addition to historical information, this press release may
contain forward-looking statements. Such statements are based on
management's current expectations and are subject to a number of
risks and uncertainties, including matters not yet known to us or
not currently considered material by us, and there can be no
assurance that anticipated events will occur or that the objectives
set out will actually be achieved. Important factors that could
cause actual results to differ materially from the results
anticipated in the forward-looking statements include, among
others, the clinical status and market acceptance of our HIFU
devices and the continued market potential for our lithotripsy
device. Factors that may cause such a difference also may include,
but are not limited to, those described in the Company's filings
with the Securities and Exchange Commission and in particular, in
the sections "Cautionary Statement on Forward-Looking Information"
and "Risk Factors" in the Company's Annual Report on Form 20-F.
Investor Contact
CG CAPITAL
Rich Cockrell
877.889.1972
investorrelations@cg.capital
Company Contact
Blandine Confort
Investor Relations / Legal Affairs EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Aug 2024 to Sep 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Sep 2023 to Sep 2024